According to the research report, the global rheumatoid arthritis drugs market size is expected to touch USD 70 Billion by 2030, from USD 61.05 Billion in 2022, growing with a significant CAGR of 1.72% from 2022 to 2030.
The rheumatoid arthritis drugs report
offers a comprehensive study of the current state expected at the major
drivers, market strategies, and key vendors’ growth. The report presents
energetic visions to conclude and study the market size, market hopes, and
competitive surroundings. The research also focuses on the important
achievements of the market, research & development, and regional growth of
the leading competitors operating in the market. The current trends of the
global rheumatoid arthritis drugs in conjunction with the geographical
landscape of this vertical have also been included in this report.
The report offers intricate dynamics about
different aspects of the global rheumatoid arthritis drugs market, which aids
companies operating in the market in making strategic development decisions.
The study also elaborates on significant changes that are highly anticipated to
configure growth of the global rheumatoid arthritis drugs during the forecast
period. It also includes a key indicator assessment that highlights growth
prospects of this market and estimates statistics related to growth of the
market in terms of value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/1755
| Report Coverage | Details |
| Market Size by 2030 | USD 70 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 1.72% |
| Largest Market | North America |
| Fastest Growing Market | Asia-Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Molecule, Sales Channel, Route of Administration, Geography |
This study covers a detailed segmentation
of the global rheumatoid arthritis drugs market, along with key information and
a competition outlook. The report mentions company profiles of players that are
currently dominating the global rheumatoid arthritis drugs market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- AbbVie
- Boehringer Ingelheim GmbH
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Pfizer, Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- UCB S.A.
- Johnson & Johnson Services, Inc.
- Amgen, Inc.
Market Segmentation
- Pharmaceuticals
- NSAIDs
- Analgesics
- DMARDs
- Glucocorticoids
- Biopharmaceuticals
- Biologics
- TNF-α antagonists
- T-cell inhibitors
- CD20 antigen
- JAK inhibitors
- anti-IL6 biologics
- Biosimilars
- CD20 antigen
- TNF-α antagonists
By Sales Channel
- Prescription
- Over-the-Counter (OTC)
By Route of Administration
- Oral
- Parenteral
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Research Methodology
The research methodology adopted by
analysts for compiling the global rheumatoid arthritis drugs report is based on
detailed primary as well as secondary research. With the help of in-depth
insights of the market-affiliated information that is obtained and legitimated
by market-admissible resources, analysts have offered riveting observations and
authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary understanding
of the global rheumatoid arthritis drugs market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Rheumatoid Arthritis Drugs Market
5.1. COVID-19 Landscape: Rheumatoid Arthritis Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Rheumatoid Arthritis Drugs Market, By Molecule
8.1. Rheumatoid Arthritis Drugs Market, by Molecule, 2022-2030
8.1.1 Pharmaceuticals
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Biopharmaceuticals
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel
9.1. Rheumatoid Arthritis Drugs Market, by Sales Channel, 2022-2030
9.1.1. Prescription
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Over-the-Counter (OTC)
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Rheumatoid Arthritis Drugs Market, By Route of Administration
10.1. Rheumatoid Arthritis Drugs Market, by Route of Administration, 2022-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Rheumatoid Arthritis Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.1.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.2.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.3.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
Chapter 12. Company Profiles
12.1. AbbVie
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Boehringer Ingelheim GmbH
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Regeneron Pharmaceuticals, Inc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pfizer, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bristol-Myers Squibb Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F. Hoffmann-La Roche Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. UCB S.A.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Johnson & Johnson Services, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Amgen, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments